

Long-term Safety and Efficacy of Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

Julie M Silverstein¹; Aleksandra Gilis-Januszevska²; Mirjana Doknic³; Antonio Miguel Pico⁴; Maria Flesteriu⁵; Gerald Raverot⁶; Andrea M Isidori⁷; Jose M Garcia⁸; Beverly MK Biller⁹; Irina Bancos¹⁰; Jennifer M Ikle¹¹; Allison S Komirenko¹¹; Laurie Domrzalski¹¹; Aimee D Shu¹¹; Kevin CJ Yuen¹²

¹Division of Endocrinology, Metabolism & Lipid Research, WashU Medicine, St. Louis, MO, USA;

²Department of Endocrinology, Jagiellonian University, Medical College, Kraków, Poland; ³University Clinical Center of Serbia, Belgrade, Serbia; ⁴Department of Clinical Medicine, Miguel Hernandez University, Alicante, Spain; ⁵Department of Medicine and Neurological Surgery, Pituitary Center, Oregon Health and Science University, Portland, OR, USA; ⁶Hospices Civils de Lyon, Lyon Cedex 03, France; ⁷Sapienza University of Rome, Roma, Italy; ⁸University of Washington/GRECC, Puget Sound VA/ Seattle, WA, USA; ⁹Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; ¹⁰Mayo Clinic, Rochester, MN, USA;

¹¹Ascendis Pharma, LLC, Palo Alto, CA, USA; ¹²Barrow Neurological Institute, University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, AZ, USA

Introduction



GH deficiency in adults can either be persistence of pediatric GH deficiency into adulthood or newly developed during adulthood



GH deficiency is associated with increased body fat, reduced muscle mass and strength, low bone density, dyslipidemia, fatigue, impaired cognition, elevated cardiovascular risk, and reduced quality of life in adults^{1,2}



Treatment for GH deficiency includes daily somatropin injections, which may adversely affect adherence in children and adults³




Suboptimal adherence and persistence to daily somatropin has been associated with less favorable clinical outcomes, underscoring the need for less burdensome treatments^{4,5}

GH, growth hormone.

1. Yuen KCJ, et al. *Endocr Pract.* 2019;25(11):1191-1232. 2. Molitch ME, et al. *J Clin Endocrinol Metab.* 2011;96(6):1587-1609. 3. Rosenfeld RG, et al. *Endocr Pract.* 2008; 14(2): 143-154. 4. Feldt-Rasmussen U, et al. *Endotext.* South Dartmouth (MA) 2000. 5. Loftus J, et al. *Front Endocrinol.* 2022; 13: 1014743.

Lonapegsomatropin (TransCon[®] hGH) Design




Lonapegsomatropin is a prodrug of somatotropin administered once weekly, designed to provide sustained release of active, unmodified somatotropin^{1,2}

Lonapegsomatropin is approved in the US and EU for pediatric GH deficiency and was approved in the US for adults with GH deficiency in July 2025 based on the phase 3 foresiGHt trial³

GH, hormone; hGH, human growth hormone.

1. Sprogø K, et al. *Endocr Connect.* 2017;6(8):R171-R181. 2. Thornton PS, et al. *J Clin Endocrinol Metab.* 2021;106(11):3184-3195. 3. Biller B, et al. *J Clin Endocrinol Metab.* 2025; doi: 10.1210/clinem/dgaf680

Extension trial to the foreSiGHt trial



Trial Population

- Of the 248 participants that completed treatment in the foreSiGHt trial:
 - 220 (88.7%) continued into the extension trial for up to 90 weeks
 - 202 (91.8%) participants completed 52 weeks of treatment in the extension trial

Regions

- North America, Europe, Asia, and Oceania

Objective

- Evaluate the long-term safety of once-weekly lonapegsomatropin in adults with GH deficiency previously treated in the foreSiGHt trial

Safety Endpoints

- AEs, laboratory values, vital signs, immunogenicity, 12-lead ECGs, fundoscopy

AE, adverse event; ECG, electrocardiogram; GH, growth hormone.

Baseline demographics and characteristics at the start of the extension trial

Safety Analysis Population	Lonapegsomatropin/ Lonapegsomatropin (N = 73)	Placebo/ Lonapegsomatropin (N = 73)	Somatropin/ Lonapegsomatropin (N = 74)	Total (N = 220)
Age, mean (SD)	43.6 (13.1)	44.2 (14.3)	41.6 (13.8)	43.4 (13.8)
> 60 years, n (%)	10 (13.7)	9 (12.3)	8 (10.8)	27 (12.3)
Female, n (%)	37 (50.7)	32 (43.8)	31 (41.9)	100 (45.5)
GH deficiency onset				
Adulthood, n (%)	42 (57.5)	38 (52.1)	42 (56.8)	122 (55.5)
Childhood, n (%)	31 (42.5)	35 (47.9)	32 (43.2)	98 (44.5)
BMI, mean (SD) (kg/m ²)	27.0 (5.0)	28.6 (6.7)	28.7 (6.7)	28.1 (6.2)
Etiology of GH deficiency ^a				
Hypothalamic-pituitary surgery	30 (41.1)	27 (37.0)	24 (32.4)	81 (36.8)
Pituitary tumor	20 (27.4)	23 (31.5)	23 (31.1)	66 (30.0)
Structural hypothalamic-pituitary defect	12 (16.4)	18 (24.7)	10 (13.5)	40 (18.2)
Idiopathic	11 (15.1)	8 (11.0)	12 (16.2)	31 (14.1)
Genetic ^b	6 (8.2)	4 (5.5)	7 (9.5)	17 (7.7)
Cranial irradiation	2 (2.7)	5 (6.8)	6 (8.1)	13 (5.9)
Traumatic brain injury	1 (1.4)	1 (1.4)	2 (2.7)	4 (1.8)
Other ^c	6 (8.2)	8 (11.0)	8 (10.8)	22 (10.0)

^aCategories not mutually exclusive.

^bGenetic mutations were in *PROT1*, *PROKR2*, and *GH-N*.

^cOther included: lymphocytic hypophysitis, Langerhans cell histiocytosis, pituitary apoplexy, pituitary gland necrosis, and Sheehan syndrome.

BMI, body mass index; GH, growth hormone; SD, standard deviation.

Lonapegsomatropin was well tolerated for up to 90 weeks


AEs occurring in $\geq 5\%$ of all participants, n (%)	Lonapegsomatropin-treated participants across the foreSiGHt and extension trials (N = 236)
Nasopharyngitis	23 (9.7)
Upper respiratory tract infection	22 (9.3)
Headache	19 (8.1)
COVID-19	17 (7.2)
Arthralgia	15 (6.4)
Injection site reactions ^a	12 (5.1)

- Most AEs in lonapegsomatropin-treated participants were mild or moderate
- There was a low incidence (3.8%) of treatment discontinuations due to AEs
- Injection site reactions were infrequent (5.1%) and were mild or moderate


^aCombined term (injection site atrophy, erythema, hemorrhage, pain, and cellulitis), all assessed as treatment-related by the investigator.
AE, adverse event.

Body composition outcomes were improved from foreSiGHt baseline through week 90


Trunk percent fat



Trunk fat mass





Visceral adipose tissue



Note. The difference in change from foreSiGHt baseline at week 90 was estimated using an ANCOVA model including treatment arm, region, baseline age group, sex, concomitant oral estrogen at screening (yes vs no), GH deficiency onset (adult vs childhood), and baseline value of the endpoint as covariates.

ANCOVA, analysis of covariance; GH, growth hormone; LS, least squares; SE, standard error.


Body composition outcomes were improved from foreSiGHt baseline through week 90



Note. The difference in change from foreSiGHt baseline at week 90 was estimated using an ANCOVA model including treatment arm, region, baseline age group, sex, concomitant oral estrogen at screening (yes vs no), GH deficiency onset (adult vs childhood), and baseline value of the endpoint as covariates.

ANCOVA, analysis of covariance; GH, growth hormone; LS, least squares; SE, standard error.

Weekly average IGF-1 SDS was maintained within the reference range through week 90




Note. Estimated weekly average IGF-1 SDS was calculated using the algorithm described by Lin, et al¹.

1. Lin Z, et al. *J Endocr Soc.* 2022; 6(1):bvab168. doi:10.1210/jendso/bvab168.

IGF-1, insulin-like growth factor 1; SDS, standard deviation score; SE, standard error.

Mean hemoglobin A1c remained stable through week 90



SE, standard error.

Low incidence of antibodies during the foreSiGHt and extension trials

Treatment-emergent antibodies	Lonapegsomatropin-treated participants across the foreSiGHt and extension trials (N = 236)
anti-hGH antibodies, n (%)	8 (3.4)
anti-lonapegsomatropin antibodies, n (%)	8 (3.4)
anti-PEG binding antibodies, n (%)	2 (0.9)

- Antibodies were low titer and transiently detected
- No neutralizing antibodies were detected

Note. Percent is based on the number of participants who had post-baseline assessments.
hGH, human growth hormone; PEG, polyethylene glycol.

Lonapegsomatropin was associated with improvements in TRIM-AGHD scores through week 90

Responder Analysis of TRIM-AGHD Total Score ^a			
	Lonapegsomatropin/ Lonapegsomatropin (N = 73)	Placebo/ Lonapegsomatropin (N = 73)	Somatropin/ Lonapegsomatropin (N = 74)
Number of responders at week 90 ^b % (95% CI)	30/69 43.5% (31.8, 55.2)	28/69 40.6% (29.0, 52.2)	24/67 35.8% (24.3, 47.3)
Among responders, change from foresiGHt baseline to week 90 in TRIM-AGHD, mean (SE)	-21.5 (1.79)	-19.4 (1.23)	-22.7 (2.07)

Decreased TRIM-AGHD scores following lonapegsomatropin treatment indicated a reduced burden of GH deficiency

PRO, patient-reported outcome; SE, standard error; TRIM-AGHD, treatment-related impact measure-adult growth hormone deficiency.

^aParticipants were classified as responders if the change in TRIM-AGHD total score from the start of the foresiGHt trial decreased by ≥ 10 points, consistent with the established minimal important difference.¹

^bThe number of participants meeting the responder threshold/number of participants with non-missing TRIM-AGHD total score at week 90.

1. Brod M et al. *Pharmacoecon Open*. 2018; 3: 71-80.

Lonapegsomatropin was generally well tolerated and demonstrated efficacy over 52 weeks in the open-label extension, and up to 90 weeks across the foresiGHt and extension trials

- A high percentage (88.7%) of participants rolled over from the foresiGHt trial and > 90% of these participants completed 52 weeks of treatment in the open-label extension
- Body composition parameters showed overall improvement from the foresiGHt trial baseline through the end of the extension trial
- These findings support the long-term safety and efficacy profile of once-weekly lonapegsomatropin for adults with GH deficiency

Ascendis Pharma and the authors thank the participants, caregivers, study sites, and investigators who participated in this clinical trial.

ascendispharma.com

Disclosures

Disclosure of potentially relevant conflicts for Julie M. Silverstein

- Received consulting fees from Xeris and Chiesi, has served on advisory boards for Camurus, and has served as a research investigator for Ascendis Pharma LLC, Fractyl Health Inc., Camurus, Bayer, Sparrow, Recordati, and AbbVie.

Ascendis Pharma Endocrinology Division A/S funded this trial and participated in the trial design, research, analysis, data collection, interpretation of the data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Tisheeka Graham, PhD, MPH, an employee of Ascendis Pharma.